Sugi Predict

Sugi Predict / Compounds / Asparagine

Asparagine

Asparagine

SCHEMBL1964050

CC(O)C(N)C(=O)O.NC(=O)CC(N)C(=O)O

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 2/20 0.48
▸ SLC1A3 P43003 4/20 0.44
▸ SLC1A2 P43004 4/20 0.44
▸ SLC1A1 P43005 3/20 0.44
▸ GRIK1 P39086 8/20 0.43
▸ GRIK2 Q13002 4/20 0.43
▸ GRIA4 P48058 3/20 0.43
▸ GRIK3 Q13003 3/20 0.43
▸ GRIK5 Q16478 3/20 0.43
▸ GRIA2 P42262 2/20 0.43
▸ GRIA1 P42261 1/20 0.43
▸ ALOX15 P16050 1/20 0.42
▸ BLM P54132 1/20 0.42
▸ PMP22 Q01453 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ GRM1 Q13255 1/20 0.41
▸ GRM2 Q14416 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Asparagine SCHEMBL7763890 1.00 SLC7A5 (0.48) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL1964053 1.00 SLC7A5 (0.48) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL9695773 1.00 SLC7A5 (0.48) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL3443446 0.94 SLC7A5 (0.54) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL18614518 0.94 SLC7A5 (0.54) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL20913225 0.94 SLC7A5 (0.54) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL22382261 0.93 SLC7A5 (0.42) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL8695366 0.93 PDCD1LG2 (0.44) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL8695387 0.93 PDCD1LG2 (0.44) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Asparagine SCHEMBL4616298 0.93 SLC7A5 (0.42) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018150196-A1 CELL PENETRATING PEPTIDES MODIFIED BY GLYCOSYLATION OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2018-08-23 — — WO claimed
US-4826680-A AUTOIMMUNE DISEASES DR. KURT MULLI NACHF. GMBH & CO. KG (DE) 1989-05-02 — — US claimed
EP-4331622-A2 INTEGRIN BINDING PEPTIDES AND USES THEREOF Universiteit Twente (NL) 2024-03-06 — — EP disclosed
US-20240025965-A1 INTEGRIN BINDING PEPTIDES AND USES THEREOF PRAKASH JAI (NL) 2024-01-25 — — US disclosed
US-20230407357-A1 BIOMANUFACTURING OF OLIGOSACCHARIDES AND DERIVATIVES FROM SIMPLE SUGAR ZYMTRONIX CATALYTIC SYSTEMS, INC. (US) 2023-12-21 — — US disclosed
WO-2023225364-A1 BIOMANUFACTURING OF OLIGOSACCHARIDES AND DERIVATIVES FROM SIMPLE SUGARS ZYMTRONIX CATALYTIC SYSTEMS, INC. (US) 2023-11-23 — — WO disclosed
EP-3365353-B1 INTEGRIN BINDING PEPTIDES AND USES THEREOF UNIV TWENTE (NL) 2023-11-22 — — EP disclosed
US-20230357318-A1 SOLUTION PHASE SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC SALTS MIMETOGEN PHARMACEUTICALS, INC. (CA) 2023-11-09 — — US disclosed
US-11753441-B2 Solution phase synthesis of beta-turn peptidomimetic cyclic salts MIMETOGEN PHARMACEUTICALS, INC. (CA) 2023-09-12 — — US disclosed
US-11634470-B2 Integrin binding peptides and uses thereof Prakash, Jai (NL) 2023-04-25 — — US disclosed
US-20210300966-A1 SOLUTION PHASE SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC SALTS MIMETOGEN PHARMACEUTICALS, INC. (CA) 2021-09-30 — — US disclosed
WO-2004072093-A2 ANTIMICROBIAL AGENTS FROM STREPTOCOCCUS MITIS AND STREPTOCOCCUS ORALIS THE UNIVERSITY OF BRISTOL (GB) 2004-08-26 — — WO disclosed
US-6235500-B1 BLOOD PROTEIN; FOR USE IN AMPLIFYING OXYGENATION OF ISOLATED ORGAN OR TISSUE THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2001-05-22 — — US disclosed
EP-0960130-A4 OXYGEN-BINDING HEME PROTEINS INCORPORATING CIRCULARLY-PERMUTED GLOBINS TRUSTEES FOR THE BOARD OF (US) 2001-01-31 — — EP disclosed
EP-0960130-A1 OXYGEN-BINDING HEME PROTEINS INCORPORATING CIRCULARLY-PERMUTED GLOBINS The Board of Trustees for the University of Illinois (US) 1999-12-01 — — EP disclosed
US-5770560-A TREATING REDUCED HEMOGLOBIN OXYGEN AFFINITY IN MAMMALS Fischer, James J. (US) 1998-06-23 — — US disclosed
WO-1998013386-A1 OXYGEN-BINDING HEME PROTEINS INCORPORATING CIRCULARLY-PERMUTED GLOBINS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 1998-04-02 — — WO disclosed
US-5428007-A Increasing oxygenation in hypoxic cells of normal and tumor tissue YALE UNIVERSITY (US) 1995-06-27 — — US disclosed
US-5173426-A Pure polynucleotide; for increasing tissue oxygenation in patients YALE UNIVERSITY (US) 1992-12-22 — — US disclosed
EP-0407045-A1 Safe sodium percarbonate composition TOKAI DENKA KOGYO KABUSHIKI KAISHA (JP) 1991-01-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753441-B2 Solution phase synthesis of beta-turn peptidomimetic cyclic salts PNISR, CGAS, NGLY1 SLC7A5 2485/4885SLC1A3 3404/4885SLC1A2 3970/4885
US-20210300966-A1 SOLUTION PHASE SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC SALTS PNISR, CGAS, NGLY1 SLC7A5 2485/4885SLC1A3 3404/4885SLC1A2 3970/4885
US-20230357318-A1 SOLUTION PHASE SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC SALTS PNISR, CGAS, NGLY1 SLC7A5 2485/4885SLC1A3 3404/4885SLC1A2 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.